DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20151504

A rare case of clomiphene citrate induced moderate ovarian hyperstimulation syndrome

Sheetal K. Barhate, Ameya Dudhwadkar, Rujul Jhaveri, Deepali Kharat-Kapote, Michelle Fonseca

Abstract


Clomiphene citrate is an orally active non-steroidal triphenylethylene derivative which is commonly used for ovulation induction. It is considered a safe agent and is rarely associated with ovarian hyperstimulation syndrome. This report describes a case of moderate ovarian hyperstimulation syndrome after ovulation induction with clomiphene without associated pregnancy which was managed conservatively.

Keywords


Clomiphene citrate, Ovarian hyperstimulation syndrome, Ovulation induction

Full Text:

PDF

References


Mitchell SY, Fletcher HM, Williams E. Ovarian hyperstimulation syndrome associated with clomiphene citrate. West Indian Med J. 2001;50(3):227-9.

Whelan JG, Vlahos NF. The ovarian hyperstimulation syndrome. Fertil Steril. 2000;73:883–96.

Nasseri S, Ledger WL. Clomiphene citrate in the twenty-first century. Hum Fertil (Camb). 2001;4(3):145-51.

Roge P, Emy R. Ovarian hyperstimulation syndrome in medically assisted reproduction. Rev Fr Gynecol Obstet. 1994;89(10):495-501.

Budev MM, Arroliga AC, Falcone T. Ovarian hyperstimulation syndrome. Crit Care Med. 2005;33(10 Suppl):S301-6.

Mathur R, Evbuomwan I, Jenkins J. Prevention and management of ovarian hyperstimulation syndrome. Current Obstet Gynaecol. 2005;15:132–8.

Alina OA, Luca A, Bors A. Principles of diagnosis and management in the ovarian hyperstimulation syndrome. Curr Health Sci J. 2013;39:187-92.

Klaus Fiedler, Diego Ezcurra. Predicting and preventing of Ovarian hyperstimulation syndrome(OHHS):the need for individualized not standardized treatment(management). Reprod Biol Endocrinol. 2012;10:32.